Literature DB >> 29607117

BRAF inhibitors in metastatic non-small cell lung cancer.

Geòrgia Anguera1, Margarita Majem1.   

Abstract

Entities:  

Year:  2018        PMID： 29607117      PMCID： PMC5864601          DOI： 10.21037/jtd.2018.01.129

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  20 in total

1.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Authors:  Rafael Rosell; Enric Carcereny; Radj Gervais; Alain Vergnenegre; Bartomeu Massuti; Enriqueta Felip; Ramon Palmero; Ramon Garcia-Gomez; Cinta Pallares; Jose Miguel Sanchez; Rut Porta; Manuel Cobo; Pilar Garrido; Flavia Longo; Teresa Moran; Amelia Insa; Filippo De Marinis; Romain Corre; Isabel Bover; Alfonso Illiano; Eric Dansin; Javier de Castro; Michele Milella; Noemi Reguart; Giuseppe Altavilla; Ulpiano Jimenez; Mariano Provencio; Miguel Angel Moreno; Josefa Terrasa; Jose Muñoz-Langa; Javier Valdivia; Dolores Isla; Manuel Domine; Olivier Molinier; Julien Mazieres; Nathalie Baize; Rosario Garcia-Campelo; Gilles Robinet; Delvys Rodriguez-Abreu; Guillermo Lopez-Vivanco; Vittorio Gebbia; Lioba Ferrera-Delgado; Pierre Bombaron; Reyes Bernabe; Alessandra Bearz; Angel Artal; Enrico Cortesi; Christian Rolfo; Maria Sanchez-Ronco; Ana Drozdowskyj; Cristina Queralt; Itziar de Aguirre; Jose Luis Ramirez; Jose Javier Sanchez; Miguel Angel Molina; Miquel Taron; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2012-01-26       Impact factor: 41.316

2.  Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Authors:  David Planchard; Egbert F Smit; Harry J M Groen; Julien Mazieres; Benjamin Besse; Åslaug Helland; Vanessa Giannone; Anthony M D'Amelio; Pingkuan Zhang; Bijoyesh Mookerjee; Bruce E Johnson
Journal:  Lancet Oncol       Date:  2017-09-11       Impact factor: 41.316

3.  PARAMOUNT: Final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.

Authors:  Luis G Paz-Ares; Filippo de Marinis; Mircea Dediu; Michael Thomas; Jean-Louis Pujol; Paolo Bidoli; Olivier Molinier; Tarini Prasad Sahoo; Eckart Laack; Martin Reck; Jesús Corral; Symantha Melemed; William John; Nadia Chouaki; Annamaria H Zimmermann; Carla Visseren-Grul; Cesare Gridelli
Journal:  J Clin Oncol       Date:  2013-07-08       Impact factor: 44.544

4.  Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer.

Authors:  Stephanie Cardarella; Atsuko Ogino; Mizuki Nishino; Mohit Butaney; Jeanne Shen; Christine Lydon; Beow Y Yeap; Lynette M Sholl; Bruce E Johnson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

5.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

6.  Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012.

Authors:  J Ferlay; E Steliarova-Foucher; J Lortet-Tieulent; S Rosso; J W W Coebergh; H Comber; D Forman; F Bray
Journal:  Eur J Cancer       Date:  2013-02-26       Impact factor: 9.162

7.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Authors:  Lecia V Sequist; James Chih-Hsin Yang; Nobuyuki Yamamoto; Kenneth O'Byrne; Vera Hirsh; Tony Mok; Sarayut Lucien Geater; Sergey Orlov; Chun-Ming Tsai; Michael Boyer; Wu-Chou Su; Jaafar Bennouna; Terufumi Kato; Vera Gorbunova; Ki Hyeong Lee; Riyaz Shah; Dan Massey; Victoria Zazulina; Mehdi Shahidi; Martin Schuler
Journal:  J Clin Oncol       Date:  2013-07-01       Impact factor: 44.544

8.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

Review 9.  Lung Cancer Statistics.

Authors:  Lindsey A Torre; Rebecca L Siegel; Ahmedin Jemal
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

Review 10.  Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy.

Authors:  Christina S Baik; Nathaniel J Myall; Heather A Wakelee
Journal:  Oncologist       Date:  2017-05-09
View more
  6 in total

1.  Large Pleural Effusion Secondary to Primary Signet-Ring Cell Adenocarcinoma of the Lung.

Authors:  Sarah Baroud; Sara Moustafa; Halah Ibrahim
Journal:  Cureus       Date:  2021-11-23

2.  Integrated Analysis of Transcriptome and Prognosis Data Identifies FGF22 as a Prognostic Marker of Lung Adenocarcinoma.

Authors:  Hong-Yan Liu; Hui Zhao; Wen-Xing Li
Journal:  Technol Cancer Res Treat       Date:  2019-01-01

3.  Cutaneous metastases as a presenting sign of metastatic NSCLC.

Authors:  William T McSweeney; Kimberley Tan
Journal:  J Surg Case Rep       Date:  2019-10-10

Review 4.  BRAF: A Two-Faced Janus.

Authors:  Pasquale Pisapia; Francesco Pepe; Antonino Iaccarino; Roberta Sgariglia; Mariantonia Nacchio; Gianluca Russo; Gianluca Gragnano; Umberto Malapelle; Giancarlo Troncone
Journal:  Cells       Date:  2020-11-27       Impact factor: 6.600

Review 5.  Inhibition of RAF dimers: it takes two to tango.

Authors:  Frazer A Cook; Simon J Cook
Journal:  Biochem Soc Trans       Date:  2021-02-26       Impact factor: 5.407

Review 6.  Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers.

Authors:  Manuel Caitano Maia; Meghan Salgia; Sumanta K Pal
Journal:  Nat Rev Urol       Date:  2020-03-17       Impact factor: 14.432
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.